Colon Cancer: Prevalence, Screening, Gene Expression and Mutation, and Risk Factors and Assessment

Journal of Environmental Science and Health - Part C Environmental Carcinogenesis and Ecotoxicology Reviews

Volumn 21, Issue 2, 2003, Pages 65-131

  Ahmed, Farid E ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

Author keywords

ACF; CEA; Colonoscopy; CT; Dietary factors; DNA repair; Environment; FAP; FBOT; FS; Genetics; GLPs; HNPCC; Immunohistochemistry; Optimization; QC; RER; RNA; RT PCR; SAGE; Sigmoidoscopy; Validation

Indexed keywords

BIOLOGICAL ORGANS; FRUITS; GENES; NUTRITION; RISK ASSESSMENT;

ENVIRONMENTAL CARCINOGENESIS; GENE EXPRESSION; MUTATION;

TUMORS;

ACTIVATED PROTEIN C; ACYLGLYCEROL LIPASE; ANTIGEN; CANCER GROWTH FACTOR; CARBONATE DEHYDRATASE; CARCINOEMBRYONIC ANTIGEN; CHORIONIC GONADOTROPIN BETA SUBUNIT; CYCLOOXYGENASE 2; CYTOKERATIN 20; FILAMIN; GUANYLATE CYCLASE; GUANYLATE CYCLASE ACTIVATOR; HISTONE H1; HUMAN T CELL LEUKEMIA VIRUS TYPE 1 BINDING PROTEIN; INTERSTITIAL COLLAGENASE; LAMININ; MESSENGER RNA; METALLOTHIONEIN; MUCIN 2; ONCOPROTEIN; PROTEIN C FOS; PROTEIN TYROSINE PHOSPHATASE; RETINOL DEHYDROGENASE; SCATTER FACTOR RECEPTOR; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR RECEPTOR 2; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; UNINDEXED DRUG; WNT PROTEIN;

CALORIC INTAKE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER INCIDENCE; CANCER PATIENT; CANCER RISK; CANCER SCREENING; CANCER SUSCEPTIBILITY; COLON CARCINOGENESIS; COLON CARCINOMA; COLON RADIOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC VALUE; DIETARY INTAKE; ENVIRONMENTAL FACTOR; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; GENE STRUCTURE; GENETIC SUSCEPTIBILITY; HUMAN; LIPID DIET; METASTASIS; MOLECULAR GENETICS; MORTALITY; OCCULT BLOOD TEST; ONCOGENE; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RISK ASSESSMENT; SIGMOIDOSCOPY; SIGNAL TRANSDUCTION;

ADENOMATOUS POLYPOSIS COLI; COLONIC NEOPLASMS; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DIET; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MASS SCREENING; MUTATION; PREVALENCE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; RNA;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN T-LYMPHOTROPIC VIRUS 1;

EID: 0345708286     PISSN: 10590501     EISSN: None     Source Type: Journal    
DOI: 10.1081/GNC-120026233     Document Type: Review

References (345)

1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics 2001. CA Cancer J Clin 2001; 51:15-36.
2. Cohen AM, Minsky BD, Schilsky RL. Cancer of the colon. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. Vol. 1. 5th ed. Philadelphia, PA: Lippincott-Raven, 1998:1144-1197.
3. Ahmed FE, Effect of diet on cancer and its progression in humans. Environ Carcino Ecotox Revs 1992; C10:141-180.
4. Smith RA, von Eschenbach AC, Wender R, Levin B, Byers T, Rothenberger D, Brooks D, Creasman W, Cohen C, Runowicz C, Saslow D, Cokkinides V. American cancer society guidelines for the early detection of cancer: update of the early detection guidelines for prostate, colorectal and endometrial cancers. CA Cancer J Clin 2001; 51:38-75.
5. Ries L, Eisner M, Kosary C. SEER Cancer Statistics Reviews. Bethesda 1973-1997, MD: National Cancer Institute, 2000.
6. Astler VB, Coller AF. The prognostic significance of direct extension of carcinoma of the colon and rectum. Ann Surg 1954; 139:846-851.
7. Feuer EJ, Wun LM. Dev Can: Probability of Developing or Dying of Cancer (software), version 4. Bethesda, MD: National Cancer Institute, 1999.
8. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 66:759-767.
9. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996; 87:159-170.
10. Kronborg O, Fenger C. Clinical evidence for the adenoma-carcinoma sequence. Eur J Cancer Prev 1999; 8(Suppl 1):S73-S86.
11. Rosai J. Ackerman's Surgical Pathology. 5th ed. St. Louis: Mosby, 2000.
12. Redston M. Carcinogenesis in the GI: from morphology to genetics and back again. Mod Path 2001; 4:236-245.
13. Giardiello FM, Genetic testing in hereditary colorectal cancer. JAMA 1997; 278:1278-1281.
14. Powell SM, Petersen GM, Krush AJ, Molecular diagnosis of familial adenomatous polyposis. N Engl J Med 1993; 329:1982-1987.
15. Bussey HJR. Familial Polyposis Coli: Family Studies, Histopathology, Differential Diagnosis, and Results of Treatment. Baltimore, MD: Johns Hopkins University Press, 1975.
16. Spirio L, Otterud B, Stauffer D. Linkage of variant or attenuated form of adenomatous polyposis coli to the adenomatous polyposis coli (APC) locus. Am J Hum Genet 1992; 51:92-100.
17. Watson P, Vasen HFA, Mecklin JP, Jarvinen H, Lynch HT. The risk of endometrial cancer in hereditary polyposis colorectal cancer. Am J Med 1994; 96:516-520.
18. Offit K. Colon cancer syndromes. In: Offit K, ed. Clinical Cancer Genetics. New York, NY: Wiley-Liss, Inc., 1998:125-149.
19. Bellacosa A, Genuardi M, Viel A, Ponz de Leon M. Hereditary nonployposis colorectal cancer: review of clinical, molecular genetics, and counseling aspects. Am J Med Genet 1996; 62:353-364.
20. Thibodeau SN, Bren G, Schaid D. Microsatellite stability in cancer of the proximal colon. Science 1993; 260:816-819.
21. Koreth J, O'Leary JJ, McGee JO'D. Microsatellites and PCR genomic analysis. J Pathol 1996; 178:239-248.
22. Rodriguez-Bigas MA, Boland CR, Hamilton SR, A National Cancer Institute workshop on hereditary nonpolyposis colorectal cancer syndrome: meeting highlights and Bethesda guidelines. J Nat Cancer Inst 1997; 89:1758-1762.
23. Syngal S, Fox EA, Li C, Dovidio M, Eng C, Kolodner RD, Gamber JE. Interpretation of genetic test results for hereditary nonpolyposis colorectal cancer. JAMA 1999; 282:247-253.
24. Jarvinen HJ, Mecklin J-P, Sistonen P. Screening reduces colorectal cancer rate in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 1995; 108:1405-1411.
25. Yagi OK, Akiyama Y, Nomiza T, Iwamy T, Endo M, Yuasa Y, Proaptotic gene BAX is frequently mutated in hereditary nonpolyposis colorectal cancer but not in adenomas. Gastroenterology 1998; 114:268-274.
26. Vining DJ. Virtual colonscopy. Semin. Ultrasound CT MR 1999; 20:56-60.
27. Ahlquist DA. Molecular stool screening for colorectal cancer. Using DNA markers may be beneficial, but large scale evaluation is needed. Br Med J 2000; 321:254-255.
28. Henderson AR, Rinker AD. Gastric, pancreatic, and intestinal function. In: Offit K, ed. Tietz Textbook of Clinical Chemistry. 3rd ed. Philadelphia, Pennsylvania: W.B. Saunders Co, 1999:1271-1327.
29. Hardcastle JD, Chamberlain JO, Robinson MH, Moss SM, Amar SS, Balfour TW, James PD, Mangham, MC. Randomised controlled trial of faecal occult-blood screening for colorectal cancer. Lancet 1996; 348:1472-1477.
30. Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, Ederer F. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota colon cancer control study. N Engl J Med 1993; 328:1365-1371.
31. Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996; 348:1467-1471.
32. Ahlquist DA. Fecal occult blood testing for colorectal cancer. Can we afford to do this? Gastroenterol. Clin North Am 1997; 26:41-55.
33. Meyer RJ. Gastrointestinal tract cancer. In: Fauci BE, Isselbacher KD, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. New York: McGraw Hill, Harrison's Principles of Internal Medicine. 14th ed. 1998:568-578.
34. Bawley OW, Kramer BS. Prevention and early detection of cancer. In: Fauci BE, Isselbacher KD, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. New York: McGraw Hill, Harrison's Principles of Internal Medicine. 14th ed. 1998:499-505.
35. Loren DE, Lewis J, Kochman ML. Colon cancer: detection and prevention. Gastroent Clinics North Amer 2002; 31:565-586.
36. Johnson CD, Ahlquist DA. Computed tomography colonography (virtual colonoscopy): a new method for colorectal screening. Gut 1999; 44:301-305.
37. Levin B. Neoplasms of the large and small intestines. In: Cecil GL, Bennett JC, eds. Cecil Textbook of Medicine. 21st ed. Philadelphia, Pennsylvania: W.B. Saunders, 2000:741-750.
38. Watine J, Miedouge M, Friedberg B. Carcinoembryonic antigen as an independent prognostic factor of recurrence and survival in patients resected for colorectal liver metastases: a systematic review. Dis Colon Rectum 2001; 44:1791-1799.
39. Moertel CG, Fleming TR, Macdonald JS, Huller DG, Laurie JA, Tangen C. An evaluation of the carcinoemberyonic antigen (CEA) test for monitoring patients with resected colon cancer. JAMA 1993; 270:943-947.
40. Ahlquist DA, Harrington JJ, Burgart LJ, Roche PC. Morphometric analysis of the "mucocellular layer" overlying colorectal cancer and normal mucosa: relevance to exfoliation and stool screening. Hum Pathol 2000; 31:51-57.
41. Ahlquist DA, Shuber AP. Stool screening for colorectal cancer: evolution from occult blood to molecular markers. Clin Chim Acta 2002; 315:157-168.
42. Kohonen-Corish M, Ross VL, Doe WF, Kool DA, Edkins E, Faragher I, Wijnen J, Khar PM, Macrae F, St. John JB. RNA-based mutation screening in hereditary nonpolyposis colorectal cancer. Am J Genet 1996; 59:818-824.
43. Cawkwell L, Gray S, Murgatroyd H, Sutherland F, Haine L, Longfellow M, O'Loughlin S, Cross D, Kronborg O, Fenger C, Mapstone N, Dixon M, Quirke P. Choice of management strategy for colorectal cancer based on a diagnostic immunohistochemical test for defective mismatch repair. Gut 1999; 45:409-415.
44. Marcus VA, Madlensky L, Gryfe R, Kim H, So K, Millar A, Temple LKF, Hsieh E, Hiruki T, Jarod S, Bapat B, Sallinger S, Redston M. Immunohistochemistry for M1Hi and jMSH2: practical test for DNA mismatch repair deficient tumors. Am J Surg Pathol 1999; 23:1248-1255.
45. Lindor NM, Burgart LW, Leontovich O, Goldberg RM, Cunningham JM, Sargent DJ, Walsh-Vockley C, Petersen GM, Walsh MD, Leggett BA, Young JP, Barker MA, Jass JR, Hooper J, Gallinger S, Bapat B, Redston M, Thibodeau SN. Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumor. J Clin Oncol 2002; 20:1043-1048.
46. Slattery ML, Curtin K, Anderson K, Ma KN, Ballard L, Edwards S, Schaffer D, Potter J, Leppert M, Samowitz WS. Association between cigarette smoking, life style factors and microsatellite instability in colon tumors. J Nat Cancer Inst 2000; 92:1831-1839.
47. Traverso G, Shuber A, Levin B, Johnson C, Olsson L, Schoetz DJ Jr, Hamilton S-R, Boynton K, Kinzler KW, Vogelstein B. Detection of APC mutations in fecal and DNA from patients with colorectal tumors. N Engl J Med 2002; 346:311-320.
48. Ahlquist DA, Skoletsky JE, Boynton KA, Harrington JJ, Mahoney DW, Pierceall WE, Thibodeau SN, Shuber AP. Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology 2000; 119:1219-1227.
49. Bedi A, Pasricha PJ, Akhtar AJ, Barber JP, Bedi GC, Giardiello FM, Zehnbauer BA, Hamilton SR, Jones RJ. Inhibition of apoptosis during development of colorectal cancer. Cancer Res 1995; 55:1811-1816.
50. Strater J, Wedding U, Barth TF, Kortez K, Elsing C, Moller P. Rapid onset of apoptosis in vitro follows disruption of beta 1-integrin/matrix interactions in human colonic crypt cells. Gastroenterology 1996; 110:1776-1784.
51. Willis MS, Fuda FS, Chenault CB. (2002) Current methods of colorectal cancer screening. Med Lab Obser 2002; May:12-19.
52. Netzer P, Forster C, Biral R, Ruchti C, Neuweiler J, Stauffer E, Schonegg R, Maurer C, Husler J, Halter F, Schmassmann A. Risk factor assessment of endoscopically removed malignant colorectal polyps. Gut 1998; 43:669-674.
53. Alberts DS, Martinez ME, Roe, DJ. Lack of effect of a high-fiber cereal supplement on the recurrence of colorectal adenomas. N Engl J Med 2000; 342:1156-1162.
54. Giovannucci E, Stampfer MJ, Colditz GA. Multivitamin use, folate and colon cancer in women. Ann Intern Med 1998; 129:517-524.
55. Marcus PM, Newcomb PA. The association of calcium and vitamin D, and colon and rectal cancer in Wisconsin women. Int J Epidemiol 1998; 27:788-793.
56. Meyer F, White E. Alcohol and nutrients in relation to colon cancer in middle aged adults. Am J Epidemiol 1993; 138:225-236.
57. Michels KB, Giovannucci E, Josphipura KJ. Prospective study of fruit and vegetable consumption and incidence of colon and rectal cancers. J Nat Cancer Inst 2000; 92:1740-1752.
58. Thun MJ, Calle EE, Namboodiri MM. Risk factors for fatal colon cancer in a large prospective study. J Natl Cancer Inst 1992; 84:1291-1500.
59. Wilett WC, Stampfer MJ, Colditz GA, Rosner BA, Speizer FE. Relation of meat, fat and fiber intake to the risk of colon cancer in a prospective study among women. N Engl J Med 1990; 323:1669-1672.
60. Fung T, Hol FB, Fuchs C, Giovannucci E, Hunter DJ, Stampfer JM, Colditz GA, Willett WC. Major dietary patterns and the risk of colorectal cancer in women. Arch Intern Med 2003; 10:309-314.
61. Shibata A, Paganini-Hill A, Ross RK, Henderson BE. Intake of vegetables, fruits, beta-carotene, vitamin C and vitamin supplements and cancer incidence among the elderly: a prospective study. Br J Cancer 1992; 66:673-679.
62. Singh PN, Fraser GE. Dietary risk factors for colon cancer in a low-risk population. Am J Epidemiol 1998; 148:761-774.
63. Schatzkin A, Lanza E, Corle D. Lack of effect of a low-fat, high-fiber diet on the recurrence of colorectal adenomas. N Engl J Med 2000; 342:1149-1155.
64. Fuchs CS, Giovannucci EL, Colditz GA. Dietary fiber and the risk of colorectal cancer and adenoma in women. N Engl J Med 1999; 340:169-176.
65. Fung T, Rimm EB, Spiegelman D. Association between dietary patterns and plasma biomarkers of obesity and cardiovascular disease risk. Am J Clin Nutr 2001; 73:61-67.
66. Slattery ML, Boucher KM, Caan BJ, Potter JD, Ma K-N. Eating patterns and risk of colon cancer. Am J Epidemiol 1998; 148:4-16.
67. Randall E, Marshall JR, Brasure J, Graham S. Dietary patterns and colon cancer in western New York. Nutr Cancer 1992; 18:265-276.
68. Gerhardsson de Verdier M, Hagman U, Peters PK. Meat cooking methods and colorectal cancer: a case-reference study in Stockholm. Int J Cancer 1991; 47:520-525.
69. Giovannucci E. Insulin and colon cancer. Cancer Causes Control 1995; 6:164-179.
70. Breuer KB, Nemes K, Marr A, Rump B, Leiendeckes B, Breuer N, Goebell HA. Alcohol and cigarette smoking and the risk of colorectal adenomas. Dig Dis Sci 2000; 615:487-493.
71. Steindorf K, Tobiasz-Adanczyk B, Popiela T, Jedrychowski W, Perear M, Matyja A, Wahrendorf J. Combined risk assessment of physical activity and dietary habits on the development of colorectal cancer. A hospital-based case control study in Poland. Eur J Cancer 2000; 9:309-316.
72. Nascimbeni R, Donato F, Ghirardi M, Mariani P, Villaracci V, Salerni B. Constipation, anthranoid laxatives, melanosis coli, and colon cancer: a risk assessment using aberrant crypt foci. Cancer Epidemiol Biomarkers Prevent 2002; 11:753-757.
73. Ilyas M, Straub J, Tomlinson IPM, Bodmer WF. Genetic pathways in colorectal and other cancers. Eur J Cancer 1999; 35:335-351.
74. Ahmed FE. Application of molecular biology to biomedicine and toxicology. Environ Carcino Ecotox Revs 1995; C11:1-51.
75. Bonn D. How DNA-repair pathways may affect cancer risk. Lancet 1998; 351:42.
76. Ahmed FE. Molecular techniques for studying gene expression in carcinogenesis. Environ Carcino Ecotox Revs 2002; C20:77-116.
77. Eick S, Nicolai M, Mumberg D, Doenecke D. Human HI histories: conserved and varied sequence elements in two HI subtype genes. Eur J Cell Biol 1989; 49:110-115.
78. Albig W, Kioschis P, Poustka A, Meergans K, Doenecke D. Human histone gene organization: nonregular arrangement within a large cluster. Genomics 1997; 40:314-322.
79. Purfeind P, Hoyer-Fender S, Doenecke D, Hochhuth C, Engel W. Expression and chromosomal mapping of the gene encoding the human histone H1.1. Human Genet 1994; 94:633-639.
80. 1 binding protein. Biochim Biophys Acta 1996; 1306:9-13.
81. Xiao G, Cvijic M-E, Fong A, Harhaj EW, Uhlik MT, Waterfield M, Sung S-C. Retroviral oncoprotein Tax induces processing of NF-[Kappa]B2/p100 in T cells; evidence for the involvement of the IKK [alpha]. EMBO J 2001; 20:6805-6815.
82. Zhang L, Zhou W, Velcuescu VE, Kern SE, Hruban RH, Hamilton SR, Vogelstein B, Kinzler KW. Gene expression profiles in normal cancer cells. Science 1997; 276:1268-1272.
83. de Pagter-Holthuzen P, Jansen M, van der Kammen RA, van Schaik FMA, Sussenbach JS, Differential expression of the human insulin-like growth factor II gene. Characterization of the IGF mRNAs and mRNA encoding a putative IGFII associated protein. Biochim Biophys Acta 1988; 950:282-295.
84. Reinmuth N, Fan F, Liu W, Parikh AA, Stoeltzing O, Jung YD, Bucane CD, Radinsky R, Gollick GE, Ellis LLm. Impact of insulin-like growth factor receptor Ifunction on angiogenesis, growth and metastasis of colon cancer. Lab Invest 2002; 83:1377-1389.
85. Petrelli NJ, Bell GI, Shows TBC. enhanced levels of insulin-like growth factor messenger RNA in human colon carcinoma and liposarcoma. Cancer Res 1986; 46:6169-6173.
86. Lambert S, Vivario J, Boniver J, Gol-Winkler R. Abnormal expression and structural modification of the insulin-like growth-factor II gene in human colorectal tumors. Int J Cancer 1990; 46:405-410.
87. Freier S, Weiss O, Eran M, Fhjvbjerg A, Dahan R, Nephesh I, Safra T, Shilon E, Raz I. Expression of the insulin-like growth factors and their receptors in adenocarcinoma of the colon. Gut 1999; 44:704-708.
88. Coffey RJ Jr, Shipley GD, Moses HL. Production of transforming growth factors by human colon cancer lines. Cancer Res 1986; 46:1164-1169.
89. Massague J, Cheifetz S, Laiho M, Ralph DA, Weis FM, Zenella A. Transforming growth factor-β. Cancer Surveys 1992; 12:81-103.
90. Tsushima H, Kawata S, Tamura S, Ito N, Shirai Y, Kiso S, Imari Y, Shimomukai H, Nomura Y, Matsuda Y, Matsuzawa, Y. High levels of transforming growth factor β1 in patients with colorectal cancer: association with disease progression. Gastroenterology 1996; 110:375-382.
91. Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, Fan RS, Zborowska E, Kinzler KW, Vogelstein B, Brattain M, Willson JKV. Inactivation of the type III TGF-β receptor in colon cancer cells with micro-satellite instability. Science 1995; 268:1336-1338.
92. Robson H, Anderson E, James RD, Schofield PF. Transforming growth factor beta 1 expression in human colorectal tumors: an independent prognostic marker in a subgroup of poor prognosis patients. Br J Cancer 1996; 74:753-758.
93. Togo G, Okamoto M, Shiratori Y, Yamaji H, Kato J, Matsumura M, Sano T, Motojima T, Omak M. Does mutation of transforming growth factor-[beta] type II receptor gene play an important role in colorectal polyps. Digestive Dis Sci 1999; 44:1803-1809.
94. Blobe G, Schiemann WP, Odish HF. Mechanisms of disease: role of transforming growth factor (beta) in human disease. N Engl J Med 2000; 342:1350-1358.
95. Kushiyama Y, Fukuda R, Suetsugu H, Kazumori H, Ishihara S, Adachi K, Kinoshita Y. Site-dependent production of transforming growth factor [beta] 1 in colonic mucosa: its possible role in tumorigenesis of the colon. J Lab Clin Med 2000; 136:201-208.
96. Monteleone G, Kumberova A, Croft NM, McKenzie C, Sheer HW, MacDonald, T.T. Blocking Smad 7 TGF-[beta]1 signaling in chronic inflammatory bowel disease. J Clin Invest 2001; 108:601-609.
97. Sanes JR, Engvall E, Butkowski R, Hunter DD. Molecular heterogeneity and basal laminae isoforms of laminin and collagen IV and the neuromuscular junction and elsewhere. J Cell Biol 1990; 111:1685-1699.
98. Sordat I, Rousselle P, Chaubert P, Petermann O, Aberdan D, Bosman FT, Alghisi G-C, Sordat B. Tumor cell budding and laminin-5 expression in colorectal carcinoma can be modulated by tissue microenvironment. J Invest Dermatol 1999; 113:1140.
99. Mafune K, Ravikumar TS, Wong JM, Vow H, Chow LB, Steele, GD Jr. Expression of Mr 32,000 laminin-binding protein messenger RNA in human colon carcinoma correlates with disease progression. Cancer Res 1990; 50:3888-3891.
100. Koshikawa N, Gianelli G, Corulti V, Miyozaki K, Quaranta, V. Role of cell surface metalloproteinase MT1-MMP in epithelial cell migration over laminin 5. J Cell Biool 2000; 148:615-624.
101. Cioce V, Castronovo V, Shmookher BM, Garbisa S, Gragioni WF, Liotta CA, Sobel ME. Increased expression of the laminin receptor in human colon cancer. J Natl Cancer Inst 1991; 83:29-36.
102. Pyke C, Salo S, Ralfkiaer E, RØmer J, DanØ K, Tryggvason K. Laminin-5 is a marker of invading cancer cells in some human carcinomas and its coexpression with the receptor for urokinase plasminogen activator in budding cancer cells in colon adenocarcinoma. Cancer Res 1995; 55:4132-4139.
103. Stossel T. from signal to pseudopod. How cells control cytoplasmic actin assembly. J Biol Chem 1989; 264:18261-18264.
104. Rockwell MA, Fechheimer M, Taylor DL. A comparison of methods used to characterize gelation of actin in vitro. Cell Motil 1984; 4:197-213.
105. Gorlin JB, Yamin R, Egan S, Stewart M, Stossel TP, Kwiatkowski DJ, Harturg JH. Human endothelial actin-binding protein (ABP-280, nonmuscle Filamin): a molecular leaf spring. J Cell Biol 1990; 111:1089-1105.
106. Heath JK, White SA, Johnstone CN, Catimel B, Simpson R, Moritz RL, Tu G-F, Ji H, Whitehead RH, Groenen LC, Scott AM, Ritter G, Cohen L, Welt S, Old LJ, Nice EC, Burgess AW. The human A33 antigen is a transmembrane glycoprotein and a novel member of the immunoglobulin superfamily. Proc Natl Acad Sci USA 1997; 94:469-474.
107. Deutsch HF. Carbonic anhydrase. Int J Biochem 1987; 10:101-113.
108. Lommerholm G, Selking O, Wistrand PJ. Amount and distribution of carbonic anhydrase CAI and CAII in the gastrointestinal tract. Gastroenterology 1985; 88:1151-1161.
109. Sly WS, Parkkila S, Rajaniemi H. Differential expression of cytoplasmic carbonic anhydrases, CAI and II and membrane associated isozymes CA IX and XII in normal mucosa of large intestine and in colorectal tumors. Dig Dis Sci 2001; 46:2179-2186.
110. Jessup JM, Steele GD Jr, Cohen L. The significance of carbonic anhydrase expression in human colorectal cancer. Gastroenterology 1993; 105:820-826.
111. Fleming RE, Parkila S, Parkkila N, Rajaniemi H, Waheed A, Sly WS. Carbonic anhydrase IV expression in rat and human gastrointestinal tract regional cellular and subcellulat location. J Clin Invest 1998, 96:2907-2914.
112. Kivela AJ, Saarnio J, Karttunen T, Kivela J, Parkkila A-K, Pastorekova S, Pastorek J, Waheed A, Sly WS, Parkkila S, Rajaniemi H. Differential expression of cytoplasmic carbonic anhydrases, CAI and II and membrane associated isozymes CAIX and XII in normal mucosa of large intestine and in colorectal tumors. Dig Dis Sci 2001; 46:2179-2186.
113. Fonti R, Labella G, Caprilli R, Frieri G, Marcheggiano A, Sambuy Y. Carbonic anhydrase I reduction in colonic mucosa of patients with active ulcerative colitis. Dig Dis Sci 1998; 43:2086-2092.
114. Hill O, Kuhn M, Zucht H-D, Cetin Y, Kulaksiz H, Adermann K, Klock G, Rechkemmer G, Forssmann W-G, Mägert H-J. Analysis of the human guanylin gene and the processing and cellular localization of the peptide. Proc Natl Acad Sci USA 1995; 92:2046-2050.
115. - secretion: proposed mecxhanism and comparison with other secretagogues. Gastroenterology 1996; 111:1558-1568.
116. Cohen MB, Hawkins JA, Witte DP. Guanylin mRNA expression in human intestine and colorectal adenocarcinoma. Lab Invest 1998; 78:101-108.
117. Soref CM, Di Y-P; Hayden L, Zhao YH, Sarte MH, Wu R. Characterization of a novel airway epithelial cell specific short-chain alcohol dehydrogenase/reductase gene whose expression is up-regulated by retinoids and is involved in the metabolism of retinal. J Biol Chem 2001; 276:24194-24202.
118. Chambon P. A decade of molecular biology of retinoic acid receptors. FASEB J 1996; 10:940-954.
119. Halazonetis TD, Georgopoulos K, Greenberg ME, Leder P. C-jun dimerizes with itself and with c-fos forming complexes of different DNA binding affinities. Cell 1988; 55:917-924.
120. Stopera SA, Davie JR, Bird RP. Colonic abberant crypt foci are associated with increased expression ofc-fos: the possible role of modified c-fos expression in preneoplastic lesions in colon cancer. Carcinogenesis 1992; 13:573-578.
121. Singh A, Tong A, Ognoskie N, Meyer W, Nemunaitis J. Improved survival in patients with advanced colorectal carcinoma failing 5-fluorouracil who received irinotecan hydrochloride and have high intratumor c-fos expression. Am J Clin Oncol Cancer Clin Trials 1998; 21:466-469.
122. Bakin AV, Curran T. Role of DNA 5-methylcytosine transferase in cells transformed by fos. Science 1999; 283:387-390.
123. Fredrikson G, Tornquist H, Belfrage P. Hormone-sensitive lipase and monoacylglycerol lipase are both required for complete degradation of adipocyte triacylglycerol. Biochim Biophys Acta 1986; 876:288-293.
124. Karlsson M, Contreras JA, Hellman U, Tornqvist H, Holm C. cDNA clones, tissue distribution and identification of the catalytic triad of monoglyceride lipase. J Biol Chem 1997; 272:27218-27223.
125. Kagi JHR. Overview of metallothionein. Methods Enzymol 1991; 205:613-626.
126. Sutah I, Kohno H, Nakashima Y, Hishikawa Y, Tabara H, Tachibana M, Kubata H, Nagasu N. Concurrent expression of metallothionein, glutathione S-transferase-π, and P-glycoprotein in colorectal cancers. Dis Colon Rectum 2000; 43:221-232.
127. Jasani B, Schmid K. Significance of metallothionein overexpression in human tumors. Histopathology 1997; 31:211-214.
128. Ofner D, Maier H, Riedmann R. Immunohistochemical metallothionein expression in colorectal adenocarcinoma: correlation with tumor stage and patient survival. Virchows Arch 1994; 425:491-497.
129. Jasani B, Campbell F, Navabi H, Schmid KW, Williams GT. Colonal overexpression of metallothionein is induced by somatic mutation in morphologically normal colonic mucosa. J Pathol 1998; 184:144-147.
130. Khan WN, Frängsmyr L, Teglund S, Israelsson A, Bremer K, Hammarstrom S. Identification of three new genes and estimation of the size of the carcinoemberyonic antigen family. Genomics 1992; 14:384-390.
131. Thompson J, Mössinger S, Reichardt V, Engels U, Beauchemin N, Kommoss F, von Kleist S, Zimmermann W. A polymerase-chain reaction assay for the specific identification of transcripts encoded by individual carcinoemberyonic antigen (CEA)-gene-family members. Int J Cancer 1993; 55:311-319.
132. Shapiro S. Goals of screening. Cancer 1992; 70:1252-1258.
133. Gerhard M, Juhl H, Kalthoff H, Schriber HW, Wagner C, Neumaier S. Specific detection of carcinoembryonic antigen expressing tumor cells in bone marrow aspirates by polymerase chain reaction. J Clin Oncol 1994; 12:727-729.
134. Mori M, Mimori K, Inoue H, Barnard GF, Tsuji K, Nanbara S, Meo H, Akiyoshi T. Detection of cancer micrometastases in lymph nodes by reverse transcriptase-polymerase chain reaction. Cancer Res 1995; 55:3417-3420.
135. Funaki NO, Tanaka J, Kasamatsu T, Ohshio G, Hosotani R, Okino T, Imamura M. Identification of carcinoembryonic antigen mRNA in circulating peripheral blood of pancreatic carcinoma and gastric carcinoma patients. Life Sci 1996; 59:2187-2199.
136. Jonas S, Windeatt S, Boateng A-O, Fordy C, Allen-Mersh TG. Identification of carcinoembryonic antigen-producing cells circulating in the blood of patients with colorectal carcinoma by reverse transcriptase polymerase chain reaction. Gut 1996; 39:717-721.
137. Lieffers G-J, Cleton-Jansen A-M, van de Velde CJH, Hermans J, van Krieken HJM, Cornelisse CJ, Tollenaar AEM. Micrometastases and survival in stage II colorectal cancer. JAMA 1998; 339:223-228.
138. Mori M, Mimori K, Ueo H, Tsuji K, Shiraishi T, Barnard GF, Sugimachi K, Akiyashi T. Clinical significance of molecular detection of carcinoma cells in lymph nodes and peripheral blood by reverse transcription-polymerase chain reaction in patients with gastrointestinal or breast carcinomas. J Clin Oncol 1998; 16:128-132.
139. Wharton RQ, Jonas SK, Glover C, Kahn ZAJ, Klokouzas A, Quinn H, Henry M, Allen-Mersh TG. Increased detection of circulating tumor cells in the blood of colorectal carcinoma patients using two reverse transcription-PCR assays and multiple blood samples. Clin Cancer Res 1999; 5:4158-4163.
140. Rosenberg R, Hoos A, Mueller J, Nekarda H. Impact of cytokeratin-20 and carcinoemberyonic antigen mRNA detection by RT-PCR in regional lymph nodes of patients with colorectal cancer. Br J Cancer 2000; 83:1323-1329.
141. Silva JM, Rodriguez R, Garcia JM, Munoz C, Silva J, Dominguez G, Provencio M, Espana P, Bonilla F. Detection of epithelial tumor RNA in the plasma of colon cancer patients is associated with advanced stages and circulating tumor cells. Gut 2002; 50:530-534.
142. Ko Y, Klinz M, Totzke G, Gouni-Berthold I, Sachinidis A, Vetter H. Limitations of the reverse transcription-polymease chain method to the detection of carcinoembryonic antigen positive tumorcells in peripheral blood. Clin Cancer Res 1998; 4:2141-2146.
143. Douard R, Le aire V, Wind P, Sales J-P, Dumas F, Fayemendi L, Landi B, Benichou J, Cugnenc P-H, Gayral F, Loric S. Carcinoembryonic gene member 2 mRNA expression as a marker to detect circulating enterocytes in the blood of colorectal cancer patients. Surgery 2001; 129:587-594.
144. Burchill SA, Bradbury MF, Pittman K, Southgate J, Smith B, Selby P. Detection of epithelial cancer cells in peripheral blood by reverse transcriptase-polymerase chain reaction. Br J Cancer 1995; 71:278-281.
145. Moll R, Zimbelmann R, Goldschmidt MD, Keith M, Laufer J, Kasper M, Koch PJ, Franke WW. The human gene coding cytokeratin 20 and its expression during development and in gastrointestinal carcinomas. Differentiation 1993; 53:75-93.
146. Chu P, Wu E, Weiss LM. Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases. Mol Pathol 2000; 13:962-972.
147. Wildi S, Kleef J, Maruyama H, Maurer CA, Friess H, Büchler MW, Lander AD, Korc M. Characterization of cytokeratin 20 expression in pancreatic and colorectal cancer. Clin Cancer Res 1999; 5:2840-2847.
148. Gum J, McCall JL, You K, Wright PA. Detection of micrometastases in colorectal cancer products by K19 and K20 reverse-transcription polymerase chain reaction. Lab Invest 1996; 75:611-616.
149. Soeth E, Röder C, Juhl H, Krüger U, Kremer B, Kalthoff H. The detection of disseminated tumor cells in bone marrow from colorectal-cancer patients by a cytokeratin-20-specific nested reverse-transcriptase-polymerase-chain reaction is related to the stage of disease. Int J Cancer (Pred Oncol) 1996; 69:278-282.
150. Denis MG, Lipart C, Le Borgne J, Le Hur P-A, Galmiche J-P, Denis M, Ruud E, Truchaud A, Lustenberger P. Detection of disseminated tumor cells in peripheral blood of colorectal cancer patients 1997; 74:540-544.
151. Funaki NO, Tanaka J, Itami A, Kasamatsu T, Ohshio G, Onodera H, Monden K, Okino T, Imamura M. Detection of colorectal carcinoma cells in circulating peripheral blood by reverse transcription-polymerase chain reaction targeting cytokeratin-20 mRNA. Life Sci 1997; 60:643-652.
152. Nakamori S, Kameyama M, Furukawa H, Osamu T, Sugui S, Imaoka S, Hakamura Y. Genetic detection of colorectal cancer cells in circulation and lymph nodes. Dis Colon Rectum 1997, 40(Suppl):S29-S36.
153. Futamura M, Takagi Y, Koumura H, Kida H, Tanemura H, Shimokawa K, Saji S. Spread of colorectal cancer micrometastases in regional lymph nodes by reverse transcriptase-polymersae chain reaction for carcinoembryonic antigen and cytokeratin 20. J Surg Oncol 1998; 68:34-40.
154. Funaki N, Tanaka J, Onodera H, Maetani S, Imamura M. Cytokeratin 20 mRNA in peripheral venous blood of colorectal carcinoma patients. Br J Cancer 1998; 77:1327-1332.
155. Little VR, Warren RS, Moore D II, Pallavicini MG. Molecular cytogenetic analysis of cytokeratin 20-labeled cells in primary tumors and bone marrow aspirates from colorectal carcinoma patients. Cancer 1996; 79:1664-1670.
156. Wyld DK, Selby P, Perren TJ, Jonas SK, Allen-Mersh TG, Wheeldon J, Burchill SA. Detection of colorectal cancer cells in peripheral blood by reverse transcriptase polymerase chain reaction for cytokeratin 20. Int J Cancer (Pred Oncol) 1998; 79:288-293.
157. Champelovier P, Mongelard F, Seigneurin D. CK20 gene expression: technical limits for the detection of circulating tumor cells. Anticancer Res 1999; 19:2073-2078.
158. Jung R, Petersen K, Krüger W, Wolf M, Wagener C, Zander A, Neumaier M. Detection of micrometastasis by cytokeratin 20 RT-PCR is limited due to stable background transcription in granulocytes. Br J Cancer 1999; 81:870-873.
159. Velms FA, Diepstra JHS, Cornelissen IMHA, Ruers TJM, Lightenberg MJL, Punt CJA, van rieken JHMJ, Wobbes T, van Muijen GNP. Limitation of cytokeratin 20 RT-PCR to detect dissiminated tumor cells in blood and bone marrow of patients with colorectal cancer: expression in controls and downregulation in tumor tissue. Mol Pathol 2002; 55:156-163.
160. Schultz S, Chrisman TD, Garbers DL. Cloning and expression of guanylin. J Biol Chem 1992; 267:16019-16021.
161. Forte LR, Currie MG. Guanylin: a peptide regulator of epithelial transport. FASEB J 1995; 9:643-650.
162. Markert T, Vaandrager AB, Gambaryan S, Pohler D, Hausler C, Walter U, DeJonge HR, Jarchase T, Lohmann SM. Endogenous expression of type II cGMP-dependent protein kinase in mRNA and protein in rat intestine. J Clin Invest 1995; 96:822-830.
163. a have different sites of action in mammalian intestine. Gastroenterology 1992; 102:1161-1169.
164. Carrithers SL, Barber MJ, Biswas S, Parkinson SJ, Park PK, Goldstein SD, Waldman SA. Guanylyl cyclase C is a selective marker for metastatic colorectal tumors in human extra intestinal tissue. Proc Natl Acad Sci USA 1996; 93:14827-14832.
165. Carrithers SL, Parkinson SJ, Goldstein SD, Park PK, Urbanski RW, Waldman SA. Escherichia coli heat-stable enterotoxin receptor. Dis Colon Rectum 1995; 39:171-181.
166. Waldman SA, Cagir B, Rakinic J, Fry RD, Goldstein SD, Isenberg G, Barber M, Biswas MS, Minimo C, Palazzo J, Park PK, Weinberg D. Use of guanyll cycloase C, for detecting micrometastasis in lymph nodes of patients with colon cancer. Dis Colon Rect 1998; 41:310-315.
167. Bustin SA, Gyselman Williams NS, Dorudi S. Detection of cytokeratin 19/ 20 and guanylyl cyclase C in peripheral blood of colorectal cancer patients. Br J Cancer 1998; 79:1813-1820.
168. + progenitor cells in peripheral blood. J Clin Oncol 2001; 19:3951-3959.
169. Cagir B, Gelmann A, Park J. Guanylyl cyclace c messenger RNA is a biomarker for recurrent stage II colorectal Cancer. Ann Intern Med 1999; 131:806-812.
170. Blank M, Klussmann E, Krüger-Krasagakes S, Schmitt-Gräff A, Stolte M, Bornhoeft G, Stein H, Ving P-X, Mckenzie IFC, Verstijnen CPHJ. Expression of MUC2-mucin in colorectal adenoma and carcinoma of different histologic types. Int J Cancer 1994; 59:301-306.
171. Hanski C, Riede E, Gratchev A, Fos HD, Döhm C, KluBmann E, Hummel M, Main B, Buhr HJ, Stein H, Kim YS, Gum J, Riecker EO. MUC2 gene suppression in human colorectal carcinoma and their metastasis: in vitro evidence of the modulatory role of DNA methylation. Lab Invest 1997; 77:685-695.
172. Buisine MP, Devisme L, Sevidge TC, Gespach C, Gosselin B, Porchet N, Aubert JP. Mucin gene expression in human embryonic and fetal intestine. Gut 1998; 43:519-524.
173. Bernini A, Spencer M, Frizelle S, Madoff RD, Willmott LD, McCormick SR, Niehaus GA, Ho SB, Kratzke RA. Evidence for colorectal cancer micrometastases using reverse transcription-polymerase chain reaction analysis of MUC2 in lymph nodes. Cancer Det Prevent 2000; 24:72-79.
174. Bresalier RS, Ho SB. Molecular staging of colorectal cancer: a step forward. Gastroenterology 1999; 116:769-774.
175. Giovarelli M, Musiani P, Garotta G, Ebner R, Di Carlo E, Kim Y, Cappello P, Rigamonti L, Bernabei P, Novelli F, Modesti A, Coletti A, Ferrie AK, Lollini P-L, Ruber S, Salcedo T, Forni G. A "stealth effect" adenocarcinoma cells engineered to express TRAIL elude tumor-specific and allogenic T cell reactions. J Immunol 1999; 163:4886-4893.
176. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholls JK, Sutherland GR, Smith TD, Rauch C, Smith CA, Goodwin RG. Identification and characterization of a member of TNF family that induces apoptosis. Immunity 1995; 3:373.
177. Hernandez A, Smith F, Wang Q, Wang X, Evers M. Assessment of differential gene expression pattern in human colon cancer. Ann Surg 2000; 232:576-585.
178. Horie T, Dobashi K, Lizuka K. Interferon gamma receives TNF-alpha-induced apoptosis mediated by up-regulation of TNFR2 on E01-1 cells. Exp Hematol 1999; 27:512-519.
179. Matter WF, Estridge T, Zhang C, Belagaje R, Stancato L, Dixon J, Johnson B, Bloem L, Pickard T, Donaghue M. Role of PRL-3, a human muscle-specific tyrosine phosphatase in angiotensin-II signaling. Biochim Biophys Res Commun 2001; 283:1061-1068.
180. Zeng Q, Si X, Horstman H, Xu Y, Hong W, Pallen CJ. Prenylation-dependent association of protein tyrosine phosphatases PRL-1, -2, and -3 with the plasma membrane in the early endosome. J Biol Chem 2000; 275:21444-21452.
181. Diamond RH, Cressman DE, Laz TM, Abrams CS, Taub R. PRL-1, a unique nuclear protein tyrosine phosphatase, affects cell growth. Mol Cell Biol 1994; 14:3752-3762.
182. CAAX protein tyrosine phosphatase. Cancer Lett 1996; 110:49-55.
183. Pardes-Zaglul A, Kang JJ, Essig Y-P, Mao W, Irby R, Wloch M, Yeatman TJ. Analysis of elevated cancer by comparative genomic hybridization: Evidence for induction of the metastatic phenotype by loss of tumor suppressor genes. Clin Cancer Res 1998; 4:879-886.
184. Saha S, Bardelli A, Buckhaults P, Velculescu VE, Rago C, Corix B, St. Romans KE, Choti MA, Lengauer C, Kinzler KW, Vogelstein B. A phosphatase associated with metastasis of colorectal cancer. Science 2001; 244:1343-1346.
185. Roelink H, Wagenaur E, Nusse R. Amplification and proximal activation of several Wnt genes during progression and clonal variation of mouse mammary tumors. Oncogene 1992; 7:482-492.
186. Lejeune S, Huguel EL, Hamby A, Poulson R, Harris AL. Wnt5a cloning, expression and up-reulation in human primary breast cancer. Clin Cancer Res 1995; 1:215-222.
187. Vider B-Z, Zimber A, Chastre E, Prevot S, Gespach C, Estlein D, Wolloch Y, Tronick SR, Gazit A, Yani A. Evidence for the involvement of Wnt2 gene in human colorectal cancer. Oncogene 1996; 12:153-158.
188. Bottaro DP, Rubin JS, Faletto DL, Chan AML, Kmiecik TE, Vande Wonde GF, Aaronson SA. Indentification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991; 251:802-804.
189. Liu C, Park M, Tsao M-S. Overexpression of c-met protooncogene but not epidermal growth factor receptor or c-erbB-2 in primary human colorectal carcinoma. Oncogene 1992; 7:181-185.
190. Chastree E, Mirossay L, Nordlinger B, Bretti S, Bottardi S, Giordano S, Plebani M, Gespach C, Omoglio PM. Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer. Clin Cancer Res 1995; 1:147-154.
191. Fujita S, Sugano K. Expression of c-met proto-oncogene in primary colorectal cancer liver metastases. Jpn J Clin Oncol 1997; 27:378-383.
192. Acevedo HF, Campbell-Acevedo EA, Buffo MJ, Krichevsky A. In vivo expression of membrane-associated human chorionic gonadotropin by cells isolated from cancerous human tissues. Proc Am Assoc Cancer Res 1994; 34:27.
193. Acevedo HF, Tong JY, Hartsock RJ. Human chorionic gonadotropin-beta subunit gene expression in cultured human fetal and cancer cells of different types of origin. Cancer 1995; 76:1467-1475.
194. Hoon DSB, Sarantou T, Doi F, Chi DDJ, Kuo C, Conrad AJ, Schmid P, Turner R, Guiliano A. Detection of metastatic breast cancer by β-hCG polynerase chain reaction. Int J Cancer (Pred Oncol) 1996; 69:369-374.
195. Hara I, Yamada Y, Miyake H, Hara S, Gotoh A, Fujisawa M, Okada H, Arakawa S, Kamidono S. Detection of β-human chorionic gonadotropin expressing cells by nested reverse transcriptase-polymerase chain reaction in the peripheral blood stem cells of patients with advanced germ cell tumor. J Urol 2002; 167:1487-1491.
196. Bilchick A, Saha S, Wiese D, Stonecypher JA, Weiss TF, Sostrin S, Turner RR, Wang H-J, Morton DL, Hoon D. Molecular staging of early colon cancer on the basis of sentinel node analysis: a multicenter phase II trial. J Clin Oncol 2001; 19:1128-1136.
197. Berns H, Humar R, Hengerr B, Kieffer FN, Battegay EJ. RACK1 is upregulated in angiogenesis and human carcinomas. FASEB J 2000; 14:2549-2558.
198. Geijsen N, Spaargaren M, Ranijmakers JAM. Association of RACK1 and PKCR with the common β chain of the IL-5/IL-3/GM-CSF receptor. Oncogene 1999; 18:5126-5130.
199. Saito A, Fujii G, Sato Y, Gotoh M, Sakamoto M, Toda G, Hirohashi S. Detection of genes expressed in primary colon cancer by in situ hybridization: overexpression of RACK1. Mol Pathol 2002; 55:34-49.
200. Okada A, Bellocq J-P, Ouyer N, Chenard M-P, Rio M-C, Chambon P, Basset P. Membrane-type matrix metalloprotein (MT-MMP) gene expressed in stromal cells of human colon, breast, and head and neck carcinomas. Proc Natl Acad Sci USA 1995; 92:2730-2734.
201. Sardinha TC, Nogures JJ, Xiong H, Weiss EG, Wexner SD, Abramson S. Membrane-type 1 matrix metalloproteinase mRNA expression in colorectal cancer. Dis. Colon Rectum 2000; 43:389-395.
202. Murray GI, Duncan ME, O'Neil P, Melvin WT, Fothergill JE. Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat Med 1996; 2:461-462.
203. Malhotra S, Newman E, Eisenberg D, Scholes J, Wieczorek R, Mignatti P, Shamamian P. Increased membrane type 1 matrix metalloproteinase expression from adenoma to colon cancer. A possible mechanism of neoplastic progression. Dis Colon Rectum 2002; 45:537-543.
204. Kjellman M, Engerg U, Hög A, Larson C, Holst M, Fornberg L-O, Sato L, Bäckdahl M, Gelatinase A, and membrane-type matrix metalloproteinase mRNA expressed in adenocortical cancers but not in adenomas. World J Surg 1999; 23:237-242.
205. Baba K, Kusumoto H, Horaguchi M, Ueo H, Akiyoshi T. Analysis of MT1-MMP and MMP2 expression in human gastric cancer. Int J Cancer 1997; 74:316-321.
206. Sandler RS, Galanko JC, Murray SC, Helm JF, Oosley JT. Asprin and nonsteroidal anti-inflammatory agents and risk for colorectal adenomas. Gastroenterology 1998; 114:441-447.
207. Sheehan KM, Sheahan K, O'Donoghue DP, MacSweeney F, Conray RM, Fitzgerald DJ, Murray FE. The relationship between cyclooxygenase expression and colorectal cancer. JAMA 1999; 282:1254-1257.
208. Oshima M, Dinchuk JE, Kargnon SL. Suppression of intestinal polyps in Apc [DELTA] 716 knockout mice by inhibition of cyclooxygenase-2 (COX-2). Cell 1996; 87:803-809.
209. Pasricha PJ, Bedi A, O'Connor K. The effects of sulinade on colorectal proliferation and apoptosis in familial adenomatous polyposia. Gastroenterology 1995; 109:994-998.
210. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998; 93:705-716.
211. Presott SM, Fitzpatrick FA. Cyclooxygenase-2 and carcinogenesis. Biochim Biophys Acta 2000; 1470:M69-M78.
212. Mackawa M, Sugano K, Sano H, Miyazaki S, Ushima M, Fujita S, Gotoda T, Yokota T, Ohtura H, Kakizoe T, Sekiga T. Increased expression of cyclooxygenase-2 to -1 in human colorectal cancers and adenomas, but not in hyperstatic polps. Jpn J Clin Oncol 1998; 28:421-426.
213. Dimberg J, Samuelsson A, Hugander A, Söderkvist P. Differential expression of cyclooxygenase 2 in human colorectal cancer. Gut 1999; 45:730-732.
214. Dixon DA, Tolley ND, King PH, Nabors LB, McIntyre TM, Zimmerman GA, Prescott SM. Altered expression of the mRNA stability factor HuR promotes cyclooxygenase-2 expression in colon cancer cells. J Clin Invest 2001; 108:1657-1665.
215. Minamoto T, Yamashita N, Ochiai A, Mai M, Sugimura T, Ronai Z, Esumi H. Mutant K-ras is apparently in normal mucosa of colorectal cancer patients. Cancer, 1995; 75:1520-1526.
216. El-Mahdani N, Vaillant J-C, Guiguet M, Prevot S, Bertrand V, Bernard C, Parc R, Berezaiat G, Hermelin B. Overexpression of p53 mRNA in colorectal cancer and its relationship to p53 gene mutation. Br J Cancer 1997; 75:528-530.
217. van Belzen N, Diesveld PG, Groen NA, van der Made ACJ, Nozawa Y, Dinjens WNM, Vlietstra R, Trapman J, Bosman FT. Identification of mRNAs that shows modulated expression during colon carcinoma cell differentiation. Eur J Biochem 1995; 243:843-848.
218. Mori M, Inoue H, Mimori K, Shibuta K, Baba K, Nakashima H, Haraguchi M, Tsuji K, Ueo H, Barnard GF, Akiyushi T. Expression of MAGE genes in human colorectal adenocarcinoma. Ann Surg 1996; 224:183-188.
219. Chi K, Jones DV, Frazier ML. Expression of a elongation factor 1 γ-related sequence in adenocarcinomas of the colon. Gastroenterology 1992; 103:98-102.
220. Solomon M, Strauss F, Varshavsky A. A mammalian high mobility group recognizes any stretch of six A-T base pairs in duplex DNA. Proc Natl Acad Sci USA 1896; 83:1276-1280.
221. Wielenga VJM, Heider K-H, Offerhaus JA, Adolf GR, van den Berg FM, Ponta H, Herrlich P, Pals ST. Expression of CD44 variant protein in human colorectal cancer is related to tumor progression. Cancer Res 1993; 53:4754-4756.
222. Vermeulen SJ, Nollet F, Teugels E, Vennekens KM, Malfait F, Philippe J, Speleman F, Bracka ME, van Roy FM, Marcell MM. The αE-catenin gene (CTNNA1) acts as an immune suppressor gene in human colon cancer cells. Oncogene 1999; 18:905-915.
223. Hiscox S, Jiang WG. Expression of E-cadherin α, β- and γ-catenin in human colorectal cancer. Anticancer Res 1997; 17:1349-1354.
224. Takayama T, Shiozaki H, Doki Y, Oka H, Inoue M, Yamamato M, Tamura S, Shibamoto S, Ito F, Monden M. Aberrant expression of phosphorylation of β-catenin in human colorectal cancer. Br J Cancer 1998; 77:605-613.
225. Bell SM, Scott N, Cross D, Sagor P, Lewis FA, Blair GE, Taylor GR, Dixon MF, Quirke P. Prognostic value of p53 overexpression and c-Ki ras gene mutations in colorectal cancer. Gastroenterology 1993; 104:57-64.
226. Samowitz WS, Holden JA, Curtin K, Edwards SL, Walker AR, Lin HA, Robertson MA, Nichols MF, Gruenthal KM, Lynch BJ, Leppert MF, Slattery ML. Inverse relationship between microsatellite instability and k-ras and p53 gene alterations in colon cancer. Am J Pathol 2001; 158:1517-1524.
227. Levine AJ, Momand J, Finlay CA. The p53 tumor suppressor gene. Nature 1991; 351:453-456.
228. Baker SJ, Fearon ER, Nigro JM, Hamilton SR, Preisinger AC, Jessup JM, Van Tuiner P, Ledbetter DH, Barker DF, Nakamura Y, White R, Vogelstein B. Chromosome 17 deletions and p53 gene mutations in colorectal carcinoma. Science 1989; 244:217-220.
229. Chen P, Chen Y, Bookstein R, Lee W. Genetic mechanisms of tumor suppression by the human p53 gene. Science 1990; 250:1576-1580.
230. Hamelin R, Laurent-Puig P, Olschwang S, Jego N, Asselain B, Remvikos Y, Girodet J, Salmon RJ, Thomas G. Association of p53 mutation with short survival in colorectal cancer. Gastroenterology 1994; 10:42-48.
231. Smith DR, Ji C-Y, Goh H-S. Prognostic significance of p53 overexpression and mutation in colorectal adenocarcinoma. Br J Cancer 1996; 74:216-230.
232. Tokunaga T, Nakamura M, Oshika Y, Tsuchida T, Kazuno M, Fukushima Y, Kawai K, Abe Y, Kijima H, Yamazaki H, Tamaoki N, Ueyama Y. Alteration in tumor suppressor gene p53 correlates with inhibition of thrombospondin-1 gene expression in colon cancer cells. Virchows Arch 1998; 433:415-418.
233. Morin N, Kelly M, Barrett N, Delaney P. Mutations of Ki-ras and p53 genes in colorectal cancer and their prognostic significance. Gut 1994; 35:1627-1631.
234. Pauly M, Schmitz M, Kayser I, Tureci O, Lagoda P, Seitz G, Dicato M. Ki-ras oncogene and p53 tumor suppressor gene mutations in colorectal carcinomas from the European Saar-Luxembourg region are less frequent than predicted by the classic adenoma-carcinoma sequence model. Eur J Cancer 1997; 33:2265-2272.
235. van Belzen N, Dinjens WNM, Eussen BHJ, Bosman FT. Expression of differentiation-related genes in colorectal carcinoma: possible implications for prognosis. Histol Histopathol 1998; 13:1233-1242.
236. van Belzen N, Dinjens WNM, Diesveld MPG, Green NA, van der Made ACJ, Nozawa Y, Vietstran R, Trapman J, Bosman FT. A novel gene which is up-regulated during colon epithelial cell differentiation and down-regulated in colorectal neoplasms. Lab Invest 1997; 77:85-92.
237. De Plaen E, Arden K, Traversari C. Structure, chromosomal localization, and expression of 12 genes of the MAGE family. Immunogenetics 1994; 40:360-369.
238. Hagesawa H, Mori M, Haraguchi M, Ueo H, Sugimachi K, Akiyoshi T. Expression spectrum of melanoma-antigen-encoding gene family members in colorectal carcinoma. Arch Pathol Lab Med 1998; 122:551-554.
239. Mori M, Mimori K, Tanaka F, Ueo H, Sugimachi K, Akiyoshi T. Molecular diagnosis of circulating cancer cells using MAGE gene assay. JAMA 1997; 278:476-477.
240. Miyashiro I, Kao C, Huynh K, Iida A, Morton D, Bilchik A, Giuliano A, Hoon DSB. Molecular strategies for detecting metastatic cancers with use of multiple tumor-specific MAGE-A genes. Clin Chem 2001; 47:505-512.
241. Lew Y, Jones DV, Mars WM, Evans D, Byrd D, Frazier ML. Expression of elongation factor-1 gamma-related sequences in human pancreatic cancer. Pancreas 1992; 7:144-152.
242. Chi K, Jones DV, Mars WM, Evans D, Byrd D, Frazier ML. Expression of elongation factor-1-γy-related sequence in human pancreatic cancer. Pancreas 1992; 7:144-152.
243. Friedmann M, Holth LT, Zoghbi HY, Reeves R. Organization, inducible expression and chromosome localization of the human HMGI(Y) nonhistone protein gene. Nucleic Acids Res 1993; 21:4259-4267.
244. Johnson KR, Lehn DA, Reeves R. Alternative processing of mRNA's coding for human HMGI and HMGY proteins. Mol Cell Biol 1989; 9:2114-2123.
245. Manfioletti G, Giancotti V, Bandiera A, Buratti E, Sautiewre P, Cary P, Crane-Robinson C, Coles B, Goodwin GH. cDNA cloning of the HMGI-c phosphoprotein, a nuclear protein associated with neoplastic and undifferentiated phenotypes. Nucleic Acids Res 1991; 19:6793-6797.
246. Zhao K, Kas E, Gonzales E, Laemmli UK. SAR-dependent mobilization of histone H1 by HMG-I/Y in vitro: HMG-I/Y is enriched in HI-depleted chromatin. EMBO J 1993; 12:3237-3247.
247. Schindler U, Baichwal VR. Three NF-κB binding sites in the human E-selectin gene required for maximal tumor necrosis factor alpha-induced expression. Mol Cell Biol 1994; 14:5820-5831.
248. Zhou X, Benson KF, Ashar HR, Chada K. Mutation responsible for the mouse pygmy phenotype in the developmentally regulated factor HMGI-C. Nature 1995; 376:771-774.
249. Fedele M, Bandiera A, Chiappetta G, Battista S, Viglietto G, Manfioletti G, Casamassimi A, Santory M, Giancotti V, Fusco A. Human colorectal carcinoma express high levels of high mobility group HMGI(Y) protein. Cancer Res 1996; 56:1896-1901.
250. Stamenkovic I, Aruffo A, Armiot M, Seed B. The hematopoietic and epithelial forms of CD44 are distinct polypeptides with different adhesion potentials for hyaluronate-bearing cells. EMBO J 1994; 39:343-349.
251. Jalkanen S, Jalkanen M, Bargatze R, Tammi M, Butcher EC. Biochemical properties of glycoproteins involved in lymphocyte recognition of high endothelial venules in man. J Immunol 1988; 44:1615-1623.
252. Tolg C, Hofmann M, Herrlich P, Ponta H. Splicing choice from ten variant exons establishes CD44 variability. Nucleic Acids Res 1993; 21:1225-1229.
253. Jackson DG, Buckley J, Bell JI. Multiple variants of the human lymphocyte homing receptor CD44 generated by insertions at a single site in the extracellular domain. J Biol Chem 1992; 267:4732-4739.
254. Herrlich P, Pals S, Ponta H. CD44 in colon cancer. Eur J Cancer 1995; 31A:1110-1112.
255. Streit M, Schmidt R, Hilgenfeld RU. Adhesion receptors in malignant transformation and dissemination of gastrointestinal tumors. J Mol Med 1996; 74:253-268.
256. Coppola D, Hyacinthe M, Fu L. CD44v6 expression in human colorectal carcinoma. Hum Pathol 1998; 29:627-635.
257. Nihei Z, Ichikawa W, Kojima K. The positive relationship between the expression of CD44 variant 6 and prognosis in colorectal cancer. Surg Today 1996; 26:760-761.
258. Finke LH, Zorb C, Haensch W. Expression of CD44 isoforms - a new histopathologic parameter in colorectal carcinoma? Zentralbl Chir 1996; 121:450-454.
259. Gunthert U, Stauder R, Mayer B. Are CD44 variant isoforms involved in human tumor progression? Cancer Surv 1995; 24:19-42.
260. Finn L, Dougherty G, Finley G. Alternative splicing of CD44 pre-mRNA in human colorectal tumors. Biochem Biophys Res Commun 1994; 200:1015-1022.
261. Yamaguchi A, Urano T, Goi T. Expression of a CD44 variant containing exons 8 to 10 is a useful independent factor for the prediction of prognosis in colorectal cancer patients. J Clin Oncol 1996; 14:1122-1127.
262. Ropponen K, Tammi M, Parkinen J. Tumor cell-associated hyaluronan as an unfavorable prognostic factor in colorectal cancer. Cancer Res 1998; 58:342-347.
263. Imazeki F, Yokosuka O, Yamaguchi T, Ohto M, Isono K, Omata M. Expression of variant DC44 messenger RNA in colorectal aenocarcinoma and adenomatous polyps in humans. Gastroenterology 1996; 110:362-368.
264. Wong LS, Cantrill JE, Odogwu S, Morris HG, Fraser IA. Detection of circulating tumor cells and nodal metastasis by reverse transcriptase-polymerase chain reaction. Br J Surg 1997; 84:834-839.
265. Gotley DC, Fawcett J, Walsh MD, Roeder JA, Simmons DL, Antalis TM. Alternatively spliced variety of the cell adhesion molecule CD44 and tumor progression in colorectal carcinoma. Br J Cancer 1996; 74:342-351.
266. Haier J, Nasralla M, Nixolson GL. Cell surface molecules and their prognostic value in colorectal carcinoma. Ann Surg 2000; 231:11-30.
267. Nagafuchi A. Molecular architecture of adherens junctions. Curr. Opin Cell Biol 2001; 13:600-603.
268. Perl A, Wilgenbus P, Dahl U, Semb H, Christofori G. A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature 1998; 392:190-193.
269. Vleminckx K, Vakaet L, Mareel M, Fiers W, van Roy F. Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell 1991; 66:107-119.
270. Conacci-Sorrell M, Zhurinsky J, Ben Ze'ev A. The cadherin-catenin adhesion system in signaling and cancer. J Clin Invest 2002; 109:987-991.
271. Tetsu O, McCormick F. Beta-Catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999; 398:422-426.
272. Streit M, Schmidt R, Hilgenfeld RU. Adhesion receptors in malignant transformation and dessimination of gastrointestinal tumors. Recent Results Cancer Res 1996; 142:19-50.
273. Mohri Y. Prognostic significance of E-cadherin expression in human colorectal cancer tissue. Surg Today 1997; 27:606-612.
274. Ilyas M, Novelli M, Wilkinson K. Tumor recurrence is associated with Jass grouping but not with differences in E-cadherin expression in moderately differentiated Dukes' B colorectal cancer. J Clin Pathol 1997; 50:218-222.
275. Kitadai Y, Ellis LM, Tucker SL. Multiparametric in situ mRNA hybridization analysis to predict disease recurrence in patients with colon carcinoma. Am J Pathol 1996; 149:1541-1551.
276. Dorudi S, Hanby AM, Poulsom R. Level of expression of E-cadherin mRNA in colorectal cancer correlates with clinical outcome. Br J, Cancer 1995; 71:614-616.
277. Takayama T, Shiozaki H, Shibamoto S. Beta-catenin expression in human cancers. Am J Pathol 1996; 148:39-46.
278. Inomata M, Ochiai A, Akimoto S. Alteration of beta-catenin expression in colonic epithelial cells of familial adenomatous polyposis patients. Cancer Res 1996; 56:2213-2217.
279. Shiozaki H, Iihara K, Oka H. Immunohistochemical detection of alpha-catenin expression in human cancers. Am J Pathol 1994; 144:667-674.
280. Ahmed FE. Molecular methods for detection of mutations. Environ Carcino Ecotox Revs 1998; C16:47-80.
281. Owens AH, Coffey DS, Baylin SB. Tumor Cell Heterogeneity: Origins and Implications. New York: Academic Press, 1982.
282. Kuecker SJ, Jin L, Kulig E, Oudrago GL, Roche PC, Lloyd RV. Analysis of PRL, PRL-R, TGFβ1, and TGFβ-RII gene expression in normal neoplastic breast tissue after laser capture microdissection. Appl Immunol Molec Morph 1999; 7:193-200.
283. Miller K. Gel electrophoresis of RNA. FOCUS (BRL) 9/3: 1993; 14-15.
284. Kacharmina J, Crino PE, Eberwine E. Preparation of cDNA from single cells and subcellular regions. Methods Enzymol 1999; 303:3-8.
285. Hardingham JE, Kotasek D, Farmer B, Butler RN, Mi JX, Sage RA, Dobrovic A. Immunobead-PCR: a technique for the detection of circulating tumor cells using immunomagnetic bead and the polymerase chain reaction. Cancer Res 1993; 53:3455-3458.
286. Hardingham JE, Hewett PJ, Sage RE, Finch JL, Nuttal JD, Kotasek D, Dobrovic A. Molecular detection of blood-borne epithelial cells in colorectal cancer patients and in patients with benign bowl disease. Int J Cancer 2000; 89:8-13.
287. Soria J-C, Morat L, Durdux C, Housset M, Corlez A, Blaise R, Sabatier L. The molecular detection of circulating tumor cells in bladder cancer using telomerase activity. J Urol 2002; 167:352-356.
288. Ghossein RA, Rosai J. Polymerase chain reaction in the detection of micrometastases and circulating tumor cells. Cancer 1996; 78:10-16.
289. Ghossein RA, Rosai J. The polymerase chain reaction in the detection of micrometastases and circulating tumor cells: present status and future potential. Anat Pathol 1998; 3:233-251.
290. Su SL, Boynton AL, Holmes EH, Elgammal AA, Murphy GP. Detection of extraprostatic prostate cells utilizing reverse transcription polymerase chain reaction. Seminars Surg Oncol 2000; 18:17-28.
291. Eaton MC, Hardingham JE, Kotasek D, Dobrovic A. Immunobead RT-PCR: a sensitive method for detection of circulating tumor cells. BioTechniques 1997; 22:100-105.
292. Clarke C, Tittley J, Davies S, O'hare MJ. An immunomagnetic separation method using supermagnetic (MACS) beads for large-scale purification of human mammary luminal and myoepithelial cells. Epithelial Cell Biol 1994; 3:38-46.
293. Johnson PWM, Burchill SA, Selby PJ. The molecular detection of circulating tumor cells. Br J Cancer 1995; 72:268-276.
294. Sidaransky D, Tokino T, Hamilton SR, Kinzly KW, Levin B, Frost P, Vogelstein B. Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. Science 1992; 256:102-105.
295. Alexander R, Raicht RE. Purification of total RNA from human stool samples. Dig Dis Sci 1998; 43:2652-2658. Fearon ER, Hamilton B, Vogelstein B. Clonal analysis of human colorectal tumors. Science 1998; 238:193-197.
296. Alexander R, Raicht RE. Purification of total RNA from human stool samples. Dig Dis Sci 1998; 43:2652-2658. Fearon ER, Hamilton B, Vogelstein B. Clonal analysis of human colorectal tumors. Science 1998; 238:193-197.
297. McPherson MJ, Moøller SG. PCR: The Basics from Background to Bench, New York: Springer-Verlag, 2000.
298. Kaufman PB, Wu W, Kim D, Cseke LJ. Analysis of gene expression by semiquantitative PCR. In Molecular and Cellular Methods in Biology and Medicine Boca Raton, Fl: CRC Press, 1995:245-262.
299. Scheuermann RH, Bauer SR. Polymerase chain reaction-based mRNA quantification using an internal standard. Methods Enzymol 1993; 218:446-473.
300. Singer M, Berg P. Determining the number of copies of a DNA sequence in a gene. In: Genes & Genomes A. Changing Perspective. Mill Valley, California: University Science Books, 1991:396-400.
301. Thellin O, Zorzi W, Lakaye B, De Borman B, Coumans B, Hensen G, Grisan T, Igout A, Heines E. Housekeeping genes as internal standards: use and limits. J Biotechnol 1999; 76:291-296.
302. Ng SY, Gunning P, Eddy R, Ponte P, Leavitt J, Shows T, Kedes L. Evolution of the functional beta-actin gene and its multi-pseudogene family: conservation of noncoding region and chromosomaldisruption of pseudogenes. Mol Cell Biol 1985; 5:2720-2732.
303. Sellner LN, Turbett GR. The presence of a pseudogene may affect the use of HPRT as an endogenous mRNA control in RT-PCR. Mol Cell Probes 1996; 10:481-483.
304. Hanauer A, Mandel JL. The glyceraldehyde 3 phosphate dehydrogenase gene family: structure of a human cDNA and of an X chromosome linked pseudogene; amazing complexity of the gene family in the mouse. EMBO J 1984; 3:2627-2633.
305. Finke J, Fritzen R, Ternes P, Lange W, Dölken G. An improved strategy and a useful housekeeping gene for RNA analysis from formalin-fixed, paraffin-embeded tissue by PCR. BioTechniques 1993; 14:448-453.
306. Bhatia P, Taylor WR, Greenberg AH, Wright JA. Comparison of glyceraldehyde-3-phosphate dehydrogenase and 28S-ribosomal RNA gene expression as RNA loading controls for Northern blot analysis of cell lines of varying malignant potential. Analyt Biochem 1994; 216:223-226.
307. Persons DA, Scheck NH, Hall BL, Finn OJ. Increased expression of glycolysis-associated genes in oncogene-transformed and growth accelerated state. Mol Carcinog 1989; 2:88-94.
308. Scheck NH, Hall BL, Finn OJ. Increased glyceraldehyde-3-phosphate dehydrogenase gene expression in human pancreatic adenocarcinoma. Cancer Res 1988; 48:6354-6359.
309. Yamada H, Chen D, Monstein H-J, Hâkanson R. Effects of fasting on the expression of gastrin, cholecystokinin and somatostatin genes and of various housekeeping genes in the pancreas and upper digestive tract of rats. Biochim Biophys Res Commun 1997; 231:835-838.
310. Darnell J, Lodish H, Baltimore D. RNA synthesis and processing. In Molecular Cell Biology. New York, NY: W. H. Freeman & Co., 1986:305-321.
311. Cross NCP. Quantitative PCR techniques and applications. Br J Haematol 1995; 89:693-697.
312. Coutlée F, He Y, Saint-Antoine P, Olivier C, Kessous M. Complications of HIV type 1 and B-globin gene DNA sequence in a nonisotopic polymerase chain reaction assay to control for amplification efficiency. AIDS Res Human Retro 1995; 11:368-371.
313. Halford WP, Falco VC, Gebhardt BM, Carp DJJ. The inherent quantitative capacity of the reverse transcription polymerase chain reaction. Anal Biochem 1999; 266:181-191.
314. Zhang C. Comparison of different quantitative PCR procedures in the analysis of the 4977-bp deletion in human mitochondrial DNA. Biochem Biophys Res Commun 1996; 223:450-455.
315. Haberhausen G, Pinsl J, Kuhn C-C, Markert-Hahn C. Comparative study of different standardization concepts in quantitative competitive reverse transcription PCR assays. J Clin Microbiol 1998; 36:628-633.
316. Ahmed FE. Molecular markers for early cancer detection. J Env Sci Health 2000; C18:75-126.
317. Gentle A, Anastasopoulos F, McBrien MA. High-resolution semi-quantitative real-time PCR without the use of a standard curve. BioTechniques 2001; 31:502-508.
318. Larrick JW, ed. The PCR Technique: Quantitative PCR. Nattick, MA: Eaton Publishing, 1998.
319. Siebert P, ed. The PCR Technique: RT-PCR. Nattick, MA: Eaton Publishing, 1998.
320. Engel RA, Villanova GJ, Lucena DJL, Arcás N, Gladón M. New approach to mRNA quantitatation: additive RT-PCR. BioTechniques 1996; 21:202-204.
321. Aqel NM, Ball RY, Waldmann H, Mitchinson MJ. Monocytic origin of foam cells in human atheroclerotic plaques. Atherosclerosis 1984; 53:265-271.
322. + lymphopenia in HIV type 2-infected individuals. AIDS Res Human Retro 1994; 10:1031-1037.
323. Villanova GJ, Dieguez J, Lucena DJL, Arcás N, Engel RA. Increased expression of scavenger receptor type I, gene in human peripheral blood from hyperlipidemic patients determined by quantitative additive RT-PCR. Biochim Biophys Acta 1996; 1300:135-141.
324. Eberwine J. Amplification of mRNA populations using primed cDNA. BioTechniques 1996; 20:584-591.
325. van Gelder R, van Zastrow M, Yool A, Dement W, Barchas J, Eberwine J. aRNA generated from immobilized oligo(dT)-Ty. Proc. Natl Acad Sci USA 1990; 87:1663-1667.
326. Madison RD, Robinson GA. λRNA internal standards qualify sensitivity and application efficiency of mammalian gene expression profiling. BioTechniques 1998; 25:504-512.
327. Mahadevappa M, Warrington JA. A high-density probe array sample preparation method using 10-100 fold fewer cells. Nature Biotechnol 1999; 17:1134-1136.
328. Hoffman L, Johnson MG. Enzymatic synthesis of milligram quantities of ribozymes in small volumes. BioTechniques 1994; 17:372-375.
329. Shanke JD. Consistent production of the highest possible RNA yields with AmpliScribe TM High Yield Transcription Kits. Epicenter Forum (Madison) 2000; 7:6-8.
330. DeMuth JP, Jackson CM, Weaver DA, Crawford EL, Durzinsky DS, Durham SJ, Zaher A, Philips ER, Khuder SA, Wiley JC. The gene expression index cmyc x E2F-1/p21 is highly predictive of malignant phenotype in human bronchial epithelial cells. Am J Respir Cell Mol Biol 1998; 19:18-29.
331. Mire-Sluis AR, Gaines-Das R, Thorpe RR. Immunoassays for detecting cytokines what are they realy measuring. J Immunol Methods 1995; 186:157-160.
332. Aziz N, Nishanian P, Mitsayasu R, Detels R, Fahey JI. Variables that affect assays for plasma cytokines and soluble activation markers. Immunol 1998; 6:89-95.
333. Longo MC, Berninger MS, Hanley JL. Use of uracil DNA glycosylase to control carryover contamination in polymerase chain reaction. Gene 1990; 93:125-128.
334. Ehrlich GD, Greenberg SJ. Commercial PCR kits. In PCR-Based Diagnostics in Infectious Disease. London: Blackwell Scientific Publications, 1994:117-129.
335. Thornton CG, Hartley JL, Rashtchian A. Utilizing uracil DNA glycosylase to control carryover contamination in PCR: characterization of residual UDG activity following thermal cycling. BioTechniques 1992; 13:181-183.
336. St. Croix B, Rago C, Velculescu V, Traverso G, Romans KE, Montgomery F, Lal A, Riggins GJ, Lengauer C, Vogelstein B, Kinzler KW. Gene expression in human tumor endothelium. Science 2000; 289:197-202.
337. Freeman WW, Walker SJ, Vrana KE. Quantitative RT-PCR: pitfalls and potential. BioTechniques 1999; 26:112-125.
338. Sardelli AD. Plateau effect-understanding PCR limitation. Amplifications (Issue 9, March 1993), 2-5, Perkin Elmer, Norwalk, CT.
339. D'Aquila RT, Bechtel LJ, Videler JA, Eron JJ, Gorczyca P, Kaylan JC. Maximizing specificity of PCR by preamplification heating. Nucl Acids Res 1991; 19:3749.
340. Klebe RJ, Rodriguez SA, VerBeek ML, Giambernardi TA. Simple method for "hot starting" RT-PCR. BioTechniques 1999; 27:1108-1110.
341. Ferre F. Quantitative or semi-quantitative PCR: reality versus myth. PCR Meth Appl 1992; 2:1-9.
342. Dutton CM, Paynton C, Sommer SS. General method for amplifying regions of high G + C content. Nucl Acids Res 1993; 21:2953-2954.
343. Defer C, Agut H, Garbarg-Chenon A, Moncany M, Morinet F, Vignon D, Mariott M, Lefrère J-J. Multicenter quality control of polymerase chain reaction for detection of HIV DNA. AIDS 1992; 6:659-663.
344. Reiss RA, Ruiz B. Quality control PCR: a method for detecting inhibitors of Taq DNA polymerase. BioTechniques 1999; 27:920-926.
345. McCormack JM, Sherman ML, Maurer DH. Quality control for DNA contamination in laboratories using PCR-based class II HLA typing methods. Human Immunol 1997; 54:82-88.